| Filed On | Filing |
|---|---|
| 18 Jun 2026 |
8-K/A: Financial Statements and Exhibits
On April 2, 2026 (the "Closing Date"), Esperion Therapeutics, Inc. (the "Company") completed the acquisition of Corstasis Therapeutics, Inc. ("Corstasis") pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), by and among... |
| 11 Aug 2025 |
8-K/A: Results of Operations and Financial Condition
Esperion Therapeutics, Inc. (the “Company”) is replacing in its entirety its earnings press release for the second quarter ended June 30, 2025, originally issued on August 5, 2025 (the “Earnings Release”), to correct certain disclosures ... |
Loading...
